Migraine has historically been managed medically, but in the last three years, four device companies have entered the market. They hope to become first-line therapies for a two- to four- million patient slice of the multibillion-dollar migraine market. Part 2 of a 2-part article on devices for migraine.
While the COVID-19 pandemic has derailed the plans of many companies in 2020, the emerging device market for the treatment of migraine has reported much good news. This year brought FDA clearances for electroCore Inc., Cefaly Technology SPRL, and Theranica Bio-Electronics Ltd.; FDA’s Breakthrough Device Designation for Salvia BioElectronics BV; and hefty Series A investments for Salvia and ShiraTronics Inc.
These announcements have focused attention on unmet medical needs that exist for millions of migraine sufferers (36-40 million in the US alone) many of whom aren’t adequately helped by many choices of drugs constituting a $1.3 billion market that is growing by more than 13% (according to a January 2020 report published by research firm Reports and Data).